

Substitute for form 1449/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/593,691-Conf. #3128
				Filing Date	December 4, 2006
				First Named Inventor	Ayumu KURIMOTO
				Art Unit	1624
				Examiner Name	M. L. Berch
(Use as many sheets as necessary)				Attorney Docket Number	0020-5516PUS1
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (If known)			
AA*	US-5,994,361		11-30-1999	Penney et al.	
AB*	US-6,110,923		08-29-2000	Ely	
AC*	US-5,736,549		04-07-1998	Beasley et al.	
AD*	US-7,157,465		01-02-2007	Isobe et al.	
AE*	US-20030212092		11-13-2003	Heppner et al.	
AF*	US-20030144283		07-31-2003	Coleman et al.	
AG*	US-20040019048		01-29-2004	Crooks et al.	
AH*	US-20040204438		10-14-2004	Crooks et al.	
AI*	US-20040229897		11-18-2004	Crooks et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
BA	JP-9-347422					
BB	JP-9-367451	JP4375901	12-2009	KAWAKAMI		
BC	JP-9-367449					
BD	CA-1220148-A1		04-07-1987	Ceskoslovenska Akademie Ved		
BE	JP-11-180981-A		07-06-1999	Sumitomo Pharma et al.		Abs
BF	JP-11-180982-A		07-06-1999	Japan Energy Corp et al.		Abs
BG	JP-2000-159767-A		06-13-2000	Sumitomo Pharma et al.		Abs
BH	JP-2005-089334-A		04-07-2005	Sumitomo Pharma		Abs
BI	JP-2004137157A-A		05-13-2004	Sumitomo Pharma		Abs
BJ	WO-2005025583-A2		03-24-2005	Anadys Pharmaceuticals Inc et al.		
BK	WO-2004087049-A2		10-14-2004	3m Innovative Properties Co		
BL	WO-2004075865-A2		09-10-2004	3m Innovative Properties Co		
BM	WO-0076519-A1		12-21-2000	3m Innovative Properties Co		

Examiner Signature	/Mark Berch/ (03/29/2010)	Date Considered	
--------------------	---------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IWF. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.B./

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	10/593,691-Conf. #3128
				Filing Date	December 4, 2006
				First Named Inventor	Ayumu KURIMOTO
				Art Unit	1624
				Examiner Name	M. L. Berch
Sheet	2	of	2	Attorney Docket Number	0020-5516PUS1

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	CA	Holy, A., et al., "9-(AMINOALKYL)-8-HYDROXYADENINES: PREPARATION, MECHANISM OF FORMATION AND USE IN AFFINITY CHROMATOGRAPHY OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE," Inst. Org. Chem. and Biochem., Czechoslovak Academy of Sciences, Vol. 51, pp 459-477 (1986)		
	CB	Kurimoto, A., et al., "Prodrugs of 9-Benzyl-8-hydroxy-2-(2-hydroxyethylthio)adenine: Potent Interferon Inducing Agents in Monkeys," Chem. Pharm. Bull. Vol 52, No 4, pp 466-469 (2004)		
	CC	Krueger, R., et al., "Tilorone Hydrochloride: An Orally Active Antiviral Agent," Science, Vol 169, pp 1213-1214 (1970)		
	CD	Mayer, G. D., et al., "Tilorone Hydrochloride: Mode of Action," Science, Vol 169, pp 1214-1215 (1970)		
	CE	Nichol, F.R., et al., "Stimulation of Murine Interferon by a Substituted Pyrimidine," Antimicro. Agents and Chemo., Vol 9, No 3, (1976)		
	CF	Stringfellow, D. A., et al., "Antiviral and Interferon-Inducing Properties of 1,5-Diamino Anthraquinones," Antimicrobial Agents and Chemo., Vol 15, No 1, pp 111-118, (1979)		
	CG	Reiter, M.J., et al., "Cytokine induction in mice by the immunomodulator imiquimod," J. Leukocyte Biol., Vol 55, pp 234-240 (1994)		
	CH	Lee, J., et al., "Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7," PNAS, Vol 100, No 11, pp 6646-6651 (2003)		
	CI	Isobe, Y., et al., "Synthesis and Biological Evaluation of Novel 9-Substituted-8-Hydroxyadenine Derivatives as Potent Interferon Inducers," J. Med. Chem., Vol 49, No 6, pp 2088-2095 (2006)		
	CJ	USPTO Office Action issue 4/8/2009 in application no 10/594,074		
	CK	USPTO Office Action issue 7/8/2009 in application no 10/594,074		
	CL	USPTO Office Action issue 10/13/2009 in application no 12/066,952		

Examiner Signature	/Mark Berch/ (03/29/2010)	Date Considered
--------------------	---------------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.B./